189 related articles for article (PubMed ID: 36110930)
41. Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways.
Javaid S; Terai K; Dudek AZ
Anticancer Res; 2015 Mar; 35(3):1279-84. PubMed ID: 25750275
[TBL] [Abstract][Full Text] [Related]
42. Cell surface chondroitin sulphate proteoglycan 4 (CSPG4) binds to the basement membrane heparan sulphate proteoglycan, perlecan, and is involved in cell adhesion.
Tang F; Lord MS; Stallcup WB; Whitelock JM
J Biochem; 2018 May; 163(5):399-412. PubMed ID: 29462330
[TBL] [Abstract][Full Text] [Related]
43. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.
Chauhan J; Grandits M; Palhares LCGF; Mele S; Nakamura M; López-Abente J; Crescioli S; Laddach R; Romero-Clavijo P; Cheung A; Stavraka C; Chenoweth AM; Sow HS; Chiaruttini G; Gilbert AE; Dodev T; Koers A; Pellizzari G; Ilieva KM; Man F; Ali N; Hobbs C; Lombardi S; Lionarons DA; Gould HJ; Beavil AJ; Geh JLC; MacKenzie Ross AD; Healy C; Calonje E; Downward J; Nestle FO; Tsoka S; Josephs DH; Blower PJ; Karagiannis P; Lacy KE; Spicer J; Karagiannis SN; Bax HJ
Nat Commun; 2023 Apr; 14(1):2192. PubMed ID: 37185332
[TBL] [Abstract][Full Text] [Related]
44. Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers.
Zhang H; Wu Z; Hu D; Yan M; Sun J; Lai J; Bai L
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891187
[TBL] [Abstract][Full Text] [Related]
45. Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.
Wiesinger M; März J; Kummer M; Schuler G; Dörrie J; Schuler-Thurner B; Schaft N
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31426437
[TBL] [Abstract][Full Text] [Related]
46. Chondroitin Sulfate Proteoglycan 4 as a Marker for Aggressive Squamous Cell Carcinoma.
Chen K; Yong J; Zauner R; Wally V; Whitelock J; Sajinovic M; Kopecki Z; Liang K; Scott KF; Mellick AS
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428658
[TBL] [Abstract][Full Text] [Related]
47. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
[TBL] [Abstract][Full Text] [Related]
48. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.
Price MA; Colvin Wanshura LE; Yang J; Carlson J; Xiang B; Li G; Ferrone S; Dudek AZ; Turley EA; McCarthy JB
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1148-57. PubMed ID: 22004131
[TBL] [Abstract][Full Text] [Related]
49. The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.
Yu L; Favoino E; Wang Y; Ma Y; Deng X; Wang X
Immunol Res; 2011 Aug; 50(2-3):294-302. PubMed ID: 21717063
[TBL] [Abstract][Full Text] [Related]
50. Functional and clinical relevance of chondroitin sulfate proteoglycan 4.
Campoli M; Ferrone S; Wang X
Adv Cancer Res; 2010; 109():73-121. PubMed ID: 21070915
[TBL] [Abstract][Full Text] [Related]
51. Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.
Uranowska K; Kalic T; Valtsanidis V; Kitzwögerer M; Breiteneder H; Hafner C
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649790
[TBL] [Abstract][Full Text] [Related]
52. Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma.
Riccardo F; Tarone L; Iussich S; Giacobino D; Arigoni M; Sammartano F; Morello E; Martano M; Gattino F; Maria R; Ferrone S; Buracco P; Cavallo F
Ther Adv Med Oncol; 2019; 11():1758835919855491. PubMed ID: 31217827
[TBL] [Abstract][Full Text] [Related]
53. Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation.
Yang J; Liao Q; Price M; Moriarity B; Wolf N; Felices M; Miller JS; Geller MA; Bendzick L; Hopps R; Starr TK; O'Connor CH; Tarullo S; Nelson AC; Turley E; Wang J; McCarthy JB
Transl Oncol; 2022 Feb; 16():101318. PubMed ID: 34942534
[TBL] [Abstract][Full Text] [Related]
54. The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.
Simon B; Wiesinger M; März J; Wistuba-Hamprecht K; Weide B; Schuler-Thurner B; Schuler G; Dörrie J; Uslu U
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103488
[TBL] [Abstract][Full Text] [Related]
55. CSPG4-dependent cytotoxicity for
Doyle DA; DeAngelis PL; Ballard JD
mSphere; 2024 Apr; 9(4):e0009424. PubMed ID: 38470254
[TBL] [Abstract][Full Text] [Related]
56. Human recombinant Fab fragment from combinatorial libraries of a B-cell lymphoma patient recognizes core protein of chondroitin sulphate proteoglycan 4.
Egami Y; Narushima Y; Ohshima M; Yoshida A; Yoneta N; Masaki Y; Itoh K
J Biochem; 2018 Jan; 163(1):61-68. PubMed ID: 29036679
[TBL] [Abstract][Full Text] [Related]
57. Diversified expression of NG2/CSPG4 isoforms in glioblastoma and human foetal brain identifies pericyte subsets.
Girolamo F; Dallatomasina A; Rizzi M; Errede M; Wälchli T; Mucignat MT; Frei K; Roncali L; Perris R; Virgintino D
PLoS One; 2013; 8(12):e84883. PubMed ID: 24386429
[TBL] [Abstract][Full Text] [Related]
58. A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model.
Uranowska K; Samadaei M; Kalic T; Pinter M; Breiteneder H; Hafner C
Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34318902
[TBL] [Abstract][Full Text] [Related]
59. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
60.
Williams IP; Crescioli S; Sow HS; Bax HJ; Hobbs C; Ilieva KM; French E; Pellizzari G; Cox V; Josephs DH; Spicer JF; Karagiannis SN; Mele S
MAbs; 2020; 12(1):1685349. PubMed ID: 31769737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]